The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, M. T.
Right arrow Articles by Lane, T. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, M. T.
Right arrow Articles by Lane, T. E.
The Journal of Immunology, 2000, 165: 2327-2330.
Copyright © 00 by The American Association of Immunologists

CUTTING EDGE

Cutting Edge: The T Cell Chemoattractant IFN-Inducible Protein 10 Is Essential in Host Defense Against Viral-Induced Neurologic Disease1

Michael T. Liu*, Benjamin P. Chen*, Patricia Oertel*, Michael J. Buchmeier{dagger}, David Armstrong{ddagger}, Thomas A. Hamilton{ddagger} and Thomas E. Lane2,*

* Department of Molecular Biology and Biochemistry, University of California, Irvine, CA 92612; {dagger} Department of Neuropharmacology, The Scripps Research Institute, La Jolla, CA 92037; and {ddagger} Department of Immunology, The Lerner Research Institute, Cleveland, OH 44195


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results and Discussion
 References
 
The contribution of the T cell chemoattractant chemokine IFN-inducible protein 10 (IP-10) in host defense following viral infection of the CNS was examined. IP-10 is expressed by astrocytes during acute encephalomyelitis in mouse hepatitis virus-infected mice, and the majority of T lymphocytes infiltrating into the CNS expressed the IP-10 receptor CXCR3. Treatment of mice with anti-IP-10 antisera led to increased mortality and delayed viral clearance from the CNS as compared with control mice. Further, administration of anti-IP-10 led to a >70% reduction (p <= 0.001) in CD4+ and CD8+ T lymphocyte infiltration into the CNS, which correlated with decreased (p <= 0.01) levels of IFN-{gamma}. These data indicate that IP-10 functions as a sentinel molecule in host defense and is essential in the development of a protective Th1 response against viral infection of the CNS.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results and Discussion
 References
 
Chemokines have been the subject of numerous studies to define the functional contributions of these molecules in inflammation (for review, see Ref. 1). Growing evidence indicates that chemokine expression represents a pivotal point in host defense by initiating specific inflammatory events that lead to leukocyte activation, extravasation, migration, and ultimately clearance of foreign Ag (2, 3, 4). IFN-inducible protein 10 (IP-10)3 is a non-ELR (glutamic acid-leucine-arginine) CXC chemokine that has been shown to be a potent chemoattractant for activated T cells and NK cells by binding to the receptor CXCR3 (5, 6, 7, 8). Both human and mouse IP-10 expression is inducible by type I and II IFNs following treatment of a wide variety of cell types (9, 10, 11, 12, 13, 14, 15, 16, 17, 18). Functionally, IP-10 is thought to contribute to various inflammatory pathologies by attracting leukocytes to sites of infection or injury (19, 20, 21, 22, 23, 24, 25, 26, 27). In addition, IP-10 exhibits antitumor properties by inhibiting angiogenesis and has recently been shown to exhibit an antiviral role (4, 28, 29).

IP-10 is expressed early within the CNS in response to infection with a wide variety of viruses (30, 31, 32, 33, 34, 35, 36, 37). Expression often represents a dominant and localized response, suggesting that IP-10 acts as a sentinel molecule in host defense by serving to initiate and maintain an inflammatory response (38). However, the contributions of IP-10 in response to viral infection of the CNS have not been fully evaluated. To assess functional significance, IP-10 activity was selectively neutralized by administration of anti-IP-10 antisera to mice infected with the neurotropic coronavirus mouse hepatitis virus (MHV). The results presented indicate that IP-10 is an essential component in host defense by coordinating the trafficking of Th1 T lymphocytes into the CNS in response to viral infection.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results and Discussion
 References
 
Virus and mice

The MHV strain V5A13.1 (referred to henceforth as MHV) was derived from wild-type MHV-4 as previously described (39). Age matched (5–7 wk), male wild-type C57BL/6 mice (H-2b background) were used for studies described. Mice were purchased from Harlan Sprague-Dawley Laboratories (San Diego, CA). Mice were injected intracranially with 10 PFU MHV suspended in 30 µl sterile saline (2). Control (sham) animals were injected with sterile saline alone. Animals were sacrificed at days 7 and 10 postinfection (p.i.), at which point brains and spinal cords were removed. One-half of each brain was used for plaque assay on the DBT astrocytoma cell line to determine viral burden (2). The remaining half of each brain was used for either RNA isolation, FACS analysis, or ELISA.

Ab preparation and treatment of mice

The generation of rabbit polyclonal antisera specific for mouse IP-10 has previously been described (28). This reagent has previously been shown to be specific for IP-10 and does not cross-react with other known chemokines (28). MHV-infected mice were divided into two groups and treated with either normal rabbit serum (NRS) or anti-IP-10. Mice were injected i.p. with 0.5 ml anti-IP-10 antisera or NRS on days 0, 2, 5, 7, and 9 p.i. and sacrificed at days 7 and 10 p.i.

Confocal microscopy

Primary Abs (diluted in PBS containing 5% normal horse serum) used for dual fluorescent detection of cellular Ags were as follows: rat anti-mouse CD4 (PharMingen, San Diego, CA) at 1:100, rat anti-mouse CD8 (PharMingen) at 1:50, and goat anti-mouse CXCR3 (Santa Cruz Biotechnology, Santa Cruz, CA) at 1:50. For CD4 and CD8 primary Abs, a TRITC-conjugated secondary Ab was used (1:50; Sigma, St. Louis, MO). For CXCR3 primary Ab, a FITC-conjugated secondary Ab was used (1:50; Zymed, South San Francisco, CA). Staining was performed on 8-µm frozen sections fixed in acetone for 10 min at -20°C. Dual-stained slides were then subjected to confocal microscopy using a Bio-Rad MRC UV laser-scanning confocal microscope (Bio-Rad, Richmond, CA).

T cell isolation and flow cytometry

Cells were obtained from brains of anti-IP-10- or NRS-treated MHV-infected mice at 7 days p.i. using a previously described protocol (2). FITC-conjugated rat anti-mouse CD4 and CD8 were used to detect infiltrating CD4+ and CD8+ T cells (PharMingen). As a control, an isotype-matched FITC-conjugated Ab was used. Cells were incubated with Abs for 30 min at 4°C, washed, fixed in 1% paraformaldehyde, and analyzed on a FACStar (Becton Dickinson, Mountain View, CA).

Ribonuclease protection assay (RPA)

Total RNA was extracted from the brains of NRS- or anti-IP-10-treated mice at day 7 p.i. using TRIzol reagent (2, 37). Cytokine transcripts were analyzed using a multitemplate probe set (mCK3; PharMingen). RPA analysis was performed using 15 µg of total RNA using a previously described protocol (2, 37).

IFN-{gamma} ELISA

IFN-{gamma} levels were quantified using the Quantikine M mouse IFN-{gamma} immunoassay kit (R&D Systems, Minneapolis, MN) using brains of mice obtained at day 7 p.i. using previously described protocols (2).

Statistical analysis

All data were analyzed by performing the Mann-Whitney Rank Sum test using Sigma Stat 2.0 software. Values of p <= 0.05 were considered significant.


   Results and Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
References
 
To determine the functional significance of IP-10 expression following viral infection of the CNS, mice were infected with a neurotropic strain of MHV, a positive-strand RNA virus. Intracranial infection of mice with MHV results in an acute encephalomyelitis followed by chronic neurologic disease in susceptible strains of mice (40, 41). The acute stage of disease is represented by widespread viral infection of neurons and glial cells, whereas the chronic stage is characterized by viral persistence in astrocytes and oligodendrocytes accompanied by mononuclear cell infiltration and myelin destruction (40, 41). IP-10 is expressed very early (day 1 p.i.) within the CNS following MHV infection and remains the predominant chemokine expressed during the acute phase of disease (37). IP-10 activity was selectively inhibited through i.p. administration of rabbit polyclonal anti-IP-10 antisera. Such treatment led to an increase in mortality with <5% of anti-IP-10-treated mice surviving until day 12 p.i. (Fig. 1Go). In marked contrast, ~50% of NRS-treated control mice survived MHV infection (Fig. 1Go). Correlating with increased mortality was a pronounced decrease in the ability of anti-IP-10-treated mice to clear virus from the CNS as compared with NRS-treated mice. Surviving anti-IP-10-treated mice displayed a 2-log increase in viral titers in the brain as compared with titers present in NRS-treated mice at day 10 p.i. (Table IGo).



View larger version (15K):
[in this window]
[in a new window]
  		FIGURE 1. Increased mortality in anti-IP-10-treated mice. Mice were infected intracranially with 10 PFU MHV and treated i.p. with either anti-IP-10 or NRS. By 12 days p.i., ~50% of NRS-treated mice survived the infection, whereas <5% of anti-IP-10-treated mice survived. Anti-IP-10, n = 27; NRS, n = 27.

 

View this table:
[in this window]
[in a new window]
  		Table I. Delayed viral clearance from the CNS in anti-IP-10-treated mice

 
Numerous studies have shown that CD4+ and CD8+ T cells are important in clearing MHV from the CNS (2, 42, 43, 44). Therefore, IP-10 expression may be important in host defense by attracting T lymphocytes into the CNS in response to viral infection. In support of this is the demonstration that the majority of infiltrating CD4+ and CD8+ T lymphocytes express the IP-10 receptor, CXCR3. CD4+ and CD8+ T lymphocytes expressing CXCR3 were present within the meninges as well as the parenchyma, indicating these cells were able to migrate into the brain (Fig. 2GoA). Flow cytometric analysis revealed that anti-IP-10 treatment of MHV-infected mice resulted in a significant decrease (p <= 0.001) in both CD4+ (82.3% decrease) and CD8+ (70.4% decrease) infiltration as compared with infected mice treated with NRS (Fig. 2GoB). Both anti-IP-10- and NRS-treated mice displayed comparable levels of monocyte/macrophage infiltration, suggesting that IP-10 does not attract these cells into the CNS following viral infection (data not shown).



View larger version (21K):
[in this window]
[in a new window]
  		FIGURE 2. A, CD4+ and CD8+ T cells express CXCR3. CXCR3 expression on CD4+ and CD8+ T cells was confirmed using confocal microscopy. Brains were removed from mice at 7 days p.i., and dual fluorescent staining for CXCR3 and CD4 or CD8 Ag was performed. Top row, Representative staining from brains of mice stained for either CXCR3 alone (green cells), CD8 (red cells), or dual-labeled CXCR3/CD8-positive cells (yellow cells). Bottom row, Representative staining from brains of mice stained for either CXCR3 (green cells), CD4 (red cells), or dual-labeled CXCR3/CD4-positive cells (yellow cells). Original magnification, x40. B, Decreased level of infiltrating T lymphoctyes within the CNS of anti-IP-10-treated mice. Single-cell suspensions were obtained from brains of infected mice at 7 days p.i., and CD4 and CD8 Ag expression was evaluated. Anti-IP-10-treated mice resulted in a 82.3% decrease in infiltrating CD4+ T cells and a 70.4% decrease in infiltrating CD8+ T cells when compared with NRS-treated mice. *, p <= 0.001. Data presented as mean ± SEM and represents the results of two independent experiments. NRS, n = 5; anti-IP-10, n = 5.

 
One potential mechanism by which infiltrating T lymphocytes contribute in host defense against MHV infection of the CNS is through the release of the antiviral cytokine IFN-{gamma} (42, 45, 46). To determine whether the decrease in T lymphocyte infiltration observed in anti-IP-10-treated mice correlated with decreased IFN-{gamma} expression, IFN-{gamma} mRNA and protein levels within the brains of anti-IP-10- and NRS-treated mice were determined by RPA and ELISA, respectively. The data shown in Fig. 3GoA indicates that neutralization of IP-10 resulted in decreased (p <= 0.05) mRNA transcripts for IFN-{gamma} as compared with transcript levels present within the brains of NRS-treated mice. Correlating with the decrease in IFN-{gamma} mRNA transcript levels was an ~80% decrease in IFN-{gamma} protein levels (NRS, 386 ± 56.7 pg/ml, n = 5; anti-IP-10, 72 ± 31 pg/ml, n = 5; p <= 0.01) at day 7 as compared with levels found in control mice treated with NRS (Fig. 3GoB). Although the levels of IFN-{gamma} mRNA transcripts in anti-IP-10-treated mice were slightly higher than would be predicted based on the IFN-{gamma} ELISA data, this is most likely due to mouse-to-mouse variation and sensitivity in the RPA and not the result of IP-10 modulating IFN-{gamma} mRNA translation.



View larger version (25K):
[in this window]
[in a new window]
  		FIGURE 3. A, Analysis of IFN-{gamma} mRNA transcripts. IFN-{gamma} mRNA transcript levels were determined by RPA analysis of total RNA obtained from brains of mice at day 7 p.i. Data is presented as normalized units representing the ratio of signal intensity of IFN-{gamma} to internal L32 included in the probe set. Values were obtained from the scanned autoradiograph using NIH Image 1.61 software (2 37 ). Data are presented as mean ± SEM. *, p <= 0.05. NRS, n = 3; anti-IP-10, n = 3. B, Decreased expression of IFN-{gamma} in anti-IP-10-treated mice. IFN-{gamma} protein levels present within the brains of mice at day 7 p.i. were determined by ELISA. Data are presented as mean ± SEM. *, p <= 0.01. NRS, n = 5; anti-IP-10, n = 5.

 
The data presented in this report have demonstrated that early and prominent expression of IP-10 within the CNS following MHV infection is important in initiating and maintaining a protective Th1 immune response characterized by high-level production of the antiviral cytokine IFN-{gamma}. IP-10 is prominently expressed within the CNS of mice following infection with other viruses such as lymphocytic choriomeningitis virus (34) and Theiler’s virus (35, 36). Therefore, based upon the data presented in this manuscript, it is not unreasonable to suggest that IP-10 may play a similar role in host defense by promoting T cell infiltration into the CNS following viral infection. However, no data on the role of IP-10 in host defense within these models or others is available. Similar to IP-10, the non-ELR CXC chemokine Mig (monokine induced by IFN-{gamma}) is induced by IFN-{gamma} and has been shown to exert a chemotactic effect upon T lymphocytes by binding to CXCR3 (6). Studies are currently in progress to evaluate the contributions of Mig to T lymphocyte infiltration into the CNS following MHV infection.

In addition to being expressed during the acute stage of MHV infection, IP-10 is expressed during chronic stages of disease almost exclusively within areas of viral persistence undergoing demyelination (37). A recent study has demonstrated that CD4+ T lymphocytes are essential in driving demyelination in mice persistently infected with MHV (2). Collectively, these observations indicate that early expression of IP-10 is beneficial through attracting Th1 T lymphocytes into the CNS that participate in viral clearance. However, chronic expression of IP-10 may ultimately be detrimental by recruiting CD4+ T cells to sites of MHV persistence, which then contribute to demyelination through the release of additional chemokines such as RANTES (2). Indeed, treatment of MHV-infected mice with anti-RANTES antisera results in a significant decrease in the severity of demyelination by reducing macrophage infiltration (2). The data presented within this study also indicates that targeting IP-10 may offer a unique target for interventional therapies for the treatment of neuroinflammatory disorders in which IP-10 is expressed and considered to contribute to neurologic disease such as multiple sclerosis (47, 48).


   Acknowledgments
 
We thank Matthew Trifilo and Wil Glass for reading the manuscript and helpful discussion.


   Footnotes
 
1 This work was supported by National Multiple Sclerosis Society Research Grant RG 30393A1/T and National Institutes of Health Grants NS37336-01 (to T.E.L.), CA39621 (to T.A.H.), and AI25913 and AI43103 (to M.J.B.). M.T.L. and B.P.C. are supported by National Institutes of Health Training Grant T32NS07444. Back

2 Address correspondence and reprint requests to Dr. Thomas E. Lane, Department of Molecular Biology and Biochemistry, University of California, 3205 Biological Sciences II, Irvine, CA 92697-3900. Back

3 Abbreviations used in this paper: IP-10, IFN-inducible protein 10; NRS, normal rabbit serum; RPA, ribonuclease protection assay; p.i., postinfection; MHV, mouse hepatitis virus. Back

Received for publication May 31, 2000. Accepted for publication June 29, 2000.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
 References
 

  1. Luster, A. D.. 1998. Chemokines—chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338:436.[Free Full Text]
  2. Lane, T. E., M. T. Liu., B. P. Chen, V. C. Asensio, R. M. Samawi, A. D. Paoletti, I. L. Campbell, S. L. Kunkel, H. S. Fox, M. J. Buchmeier. 2000. A central role for CD4+ T cells and RANTES in virus-induced central nervous system inflammation and demyelination. J. Virol. 74:1415.[Abstract/Free Full Text]
  3. Cook, D. N., M. A. Beck, T. M. Coffman, S. L. Kirby, J. F. Sheridan, I. B. Pragnell, O. Smithies. 1995. Requirement of MIP-1{alpha} for an inflammatory response to viral infection. Science 269:1583.[Abstract/Free Full Text]
  4. Mahalingam, S., J. M. Farber, G. Karupiah. 1999. The interferon-inducible chemokines MuMig and Crg-2 exhibit antiviral activity in vivo. J. Virol. 73:1479.[Abstract/Free Full Text]
  5. Loetscher, M., B. Gerber, P. Loetscher, S. A. Jones, L. Piali, I. C. Lewis, M. Baggiolini, B. Moser. 1996. Chemokine receptor specific for IP-10 and Mig: structure, function, and expression in activated T-lymphocytes. J. Exp. Med. 184:963.[Abstract/Free Full Text]
  6. Farber, J. M.. 1997. Mig and IP-10: CXC chemokines that target lymphocytes. J. Leukocyte Biol. 61:246.[Abstract]
  7. Piali, L., C. Weber, G. LaRosa, C. R. Mackay, T. A. Springer, I. Clark-Lewis, B. Moser. 1998. The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesion-induction of effector T lymphocytes by the chemokines IP10 and Mig. Eur. J. Immunol. 28:961.[Medline]
  8. Biddison, W. E., W.W. Cruikshank, D. M. Center, C. M. Pelfrey, D. D. Taub, R. V. Turner. 1998. CD8+ myelin peptide-specific T cells can chemoattract CD4+ myelin peptide-specific T cells: importance of IFN-inducible protein 10. J. Immunol. 160:444.[Abstract/Free Full Text]
  9. Farber, J. M.. 1990. A macrophage mRNA selectively induced by {gamma}-interferon encodes a member of the platelet factor 4 family of cytokines. Proc. Natl. Acad. Sci. USA 87:5238.[Abstract/Free Full Text]
  10. Farber, J. M.. 1992. A collection of mRNA species that are inducible in the RAW264.7 mouse macrophage cell line by {gamma} interferon and other agents. Mol. Cell. Biol. 12:1535.[Abstract/Free Full Text]
  11. Sauty, A., M. Dziejman, R. A. Taha, A. S. Iarossi, K. Neote, E. A. Garcia-Zepeda, Q. Hamid, A. D. Luster. 1999. The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells. J. Immunol. 162:3549.[Abstract/Free Full Text]
  12. Cassatella, M. A., S. Gasperini, F. Calzetti, A. Bertagnin, A. D. Luster, P. P. McDonald. 1997. Regulated production of the interferon-{gamma}-inducible protein-10 (IP-10) chemokine by human neutrophils. Eur. J. Immunol. 1:111.
  13. Luster, A. D., J. C. Unkeless, J. V. Ravetch. 1985. Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 315:672.[Medline]
  14. Luster, A.D., J. V. Ravetch. 1987. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J. Exp. Med. 166:1084.[Abstract/Free Full Text]
  15. Gasperini, S., M. Marchi, F. Calzetti, C. Laudanna, L. Vicentini, H. Olsen, M. Murphy, F. Liao, J. Farber, M. A. Cassatella. 1999. Gene expression and production of the monokine induced by IFN-{gamma} (MIG), IFN-inducible T cell {alpha} chemoattractant (I-TAC), and IFN-{gamma}-inducible protein-10 (IP-10) chemokines by human neutrophils. J. Immunol. 162:4928.[Abstract/Free Full Text]
  16. Narumi, S., L. M. Wyner, M. H. Stoler, C. S. Tannenbaum, T. A. Hamilton. 1992. Tissue-specific expression of murine IP-10 mRNA following systemic treatment with interferon {gamma}. J. Leukocyte Biol. 52:27.[Abstract]
  17. Ohmori, Y., T. A. Hamilton. 1993. Cooperative interaction between interferon (IFN) stimulus response element and {kappa}B sequence motifs controls IFN{gamma}- and lipopolysaccharide-stimulated transcription from the murine IP-10 promoter. J. Biol. Chem. 268:6677.[Abstract/Free Full Text]
  18. Ohmori, Y., T. A. Hamilton. 1995. The interferon-stimulated response element and a {kappa}B site mediate synergistic induction of murine IP-10 gene transcription by IFN-{gamma} and TNF-{alpha}. J. Immunol. 154:5235.[Abstract]
  19. Narumi, S., Y. Tominaga, M. Tamaru, S. Shimai, H. Okumura, K. Nishioji, Y. Itoh, T. Okanoue. 1997. Expression of IFN-inducible protein-10 in chronic hepatitis. J. Immunol. 158:5536.[Abstract]
  20. Engelhardt, E., A. Toksoy, M. Goebler, S. Debus, E. B. Brocker, R. Gillitzer. 1998. Chemokines IL-8, GRO-{alpha}, MCP-1, IP-10, and Mig are sequentially and differentially expressed during phase-specific infiltration of leukocyte subsets in human wound healing. Am. J. Pathol. 153:1849.[Abstract/Free Full Text]
  21. Bradley, L. M., V. C. Asensio, L. K. Schoitz, J. Harbertson, T. Krahl, G. Patstone, N. Woolf, I. L. Campbell, N. Sarvetnick. 1999. Islet-specific Th1, but not Th2, cells secrete multiple chemokines and promote rapid induction of autoimmune diabetes. J. Immunol. 162:2511.[Abstract/Free Full Text]
  22. Shields, P. L., C. M. Morland, M. Salmon, S. Qin, S.G. Hubscher, D. H. Adams. 1999. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J. Immunol. 163:6236.[Abstract/Free Full Text]
  23. Uguccioni, M., P. Gionchetti, D. F. Robbiani, F. Rizzello, S. Peruzzo, M. Campieri, M. Baggiolini. 1999. Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am. J. Pathol. 155:331.[Abstract/Free Full Text]
  24. Romagnani, P., C. Beltrame, F. Annunziato, L. Lasagni, M. Luconi, G. Galli, L. Cosmi, E. Maggi, M. Salvadori, C. Pupilli, M. Serio. 1999. Role for interactions between IP-10/Mig and CXCR3 in proliferative glomerulonephiritis. J. Am. Soc. Nephrol. 10:2518.[Abstract/Free Full Text]
  25. Luster, A. D., R. D. Cardiff, J. A. MacLean, K. Crowe, R. D. Granstein. 1998. Delayed wound healing and disorganized neovascularization in transgenic mice expressing the IP-10 chemokine. Proc. Assoc. Am. Phys. 110:183.[Medline]
  26. Ransohoff, R. M., T. A. Hamilton, M. Tani, M. H. Stoler, H. E. Shick, J. A. Major, M. L. Estes, D. M. Thomas, V. K. Tuohy. 1993. Astrocyte expression of mRNA encoding cytokines IP-10 and JE/MCP-1 in experimental autoimmune encephalomyelitis. FASEB J. 7:592.[Abstract]
  27. Glabinski, A. R., M. Tani, R. M. Strieter, V. K. Tuohy, R. M. Ransohoff. 1997. Synchronous synthesis of {alpha} and ß chemokines by cells of diverse lineage in the central nervous system of mice with relapses of chronic experimental autoimmune encephalomyelitis. Am. J. Pathol. 150:617.[Abstract]
  28. Tannenbaum, C. S., R. Tubbs, D. Armstrong, J. H. Finke, R. M. Bukowski, T. A. Hamilton. 1998. The CXC chemokines IP-10 and Mig are necessary for IL-12 mediated regression of the mouse RENCA tumor. J. Immunol. 161:927.[Abstract/Free Full Text]
  29. Keane, M. P., J. A. Belperio, D. A. Arenberg, M. D. Burdick, Z. J. Xu, Y. Y. Xue, R. M. Strieter. 1999. IFN-{gamma}-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J. Immunol. 163:5686.[Abstract/Free Full Text]
  30. Kolb, S. A., B. Sporer, F. Lahrtz, U. Koedel, H. W. Pfister, A. Fontana. 1999. Identification of a T cell chemotactic factor in the cerebralspinal fluid of HIV-infected individuals as interferon gamma inducible protein 10. J. Neuroimmunol. 93:172.[Medline]
  31. Farber, J. M.. 1998. Chemokines, lymphocytes, and HIV. Braz. J. Med. Biol. Res. 31:11.[Medline]
  32. Charles, P. C., X. Chen., M. S. Horwitz, C. F. Brosnan. 1999. Differential chemokine induction by the mouse adenovirus type-1 in the central nervous system of susceptible and resistant strains of mice. J. Neurovirol. 5:55.[Medline]
  33. Cheret, A., R. Le Grand, P. Caufour, O. Neildez, F. Matheux, F. Theodoro, F. Boussin, B. Vaslin, D. Dormont. 1997. Chemoattractant factors (IP-10, MIP-1{alpha}, IL-16) mRNA expression in mononuclear cells from different tissues during acute SIVmac251 infection of macaques. J. Med. Primatol. 26:19.[Medline]
  34. Asensio, V. C., I. L. Campbell. 1997. Chemokine gene expression in the brains of mice with lymphocytic choriomeningitis. J. Virol. 71:7832.[Abstract]
  35. Hoffman, L. M., B. T. Fife, W. S. Begolka, S. D. Miller, W. J. Karpus. 1999. Central nervous system chemokine expression during Theiler’s virus-induced demyelinating disease. J. Neurovirol. 5:635.[Medline]
  36. Theil, D. J., I. Tsunoda., J. E. Libbey, T. J. Derfuss, R. S. Fujinami. 2000. Alterations in cytokine but not chemokine mRNA expression during three distinct Theiler’s virus infections. J. Neuroimmunol. 104:22.[Medline]
  37. Lane, T. E., V. C. Asensio, N. Yu, A. D. Paoletti, I. L. Campbell, M. J. Buchmeier. 1998. Dynamic regulation of {alpha} and ß chemokine expression in the central nervous system during mouse hepatitis virus-induced demyelinating disease. J. Immunol. 160:970.[Abstract/Free Full Text]
  38. Asensio, V. C., C. Kincaid, I. L. Campbell. 1999. Chemokines and the inflammatory response to viral infection in the central nervous system with a focus on lymphocytic choriomeningitis virus. J. Neurovirol. 5:65.[Medline]
  39. Dalziel, R. G., P. W. Lampert, M. J. Buchmeier. 1986. Site-specific alteration of murine hepatitis virus type 4 peplomer glycoprotein E2 results in reduced neurovirulence. J. Virol. 59:463.[Abstract/Free Full Text]
  40. Houtman, J. J., J. O. Fleming. 1996. Pathogenesis of mouse hepatitis virus-induced demyelination. J. Neurovirol. 2:361.[Medline]
  41. Buchmeier, M. J., T. E. Lane. 1999. Viral-induced neurodegenerative disease. Curr. Opin. Micro. 2:398.
  42. Pearce, B. D., M. V. Hobbs, T. S. McGraw, M. J. Buchmeier. 1994. Cytokine induction during T-cell-mediated clearance of mouse hepatitis virus from neurons in vivo. J. Virol. 68:5483.[Abstract/Free Full Text]
  43. Williamson, J. S. P., S. A. Stohlman. 1990. Effective clearance of mouse hepatitis virus from the central nervous system requires both CD4+ and CD8+ T cells. J. Virol. 64:4589.[Abstract/Free Full Text]
  44. Yamaguchi, K., N. Goto, S. Kyuwa, M. Hayami, Y. Toyoda. 1991. Protection of mice from a lethal coronavirus infection in the central nervous system by adoptive transfer of virus-specific T cell clones. J. Neuroimmunol. 32:1.[Medline]
  45. Lane, T. E., A. D. Paoletti, M. J. Buchmeier. 1997. Disassociation between the in vitro and in vivo effects of nitric oxide on a neurotropic murine coronavirus. J. Virol. 71:2202.[Abstract]
  46. Parra, B., D. R. Hinton, N. W. Marten, C. C. Bergmann, M. T. Lin, C. S. Yang, S. A. Stohlman. 1999. IFN-{gamma} is required for viral clearance from central nervous system oligodendroglia. J. Immunol. 162:1641.[Abstract/Free Full Text]
  47. Sorensen, T., M. Tani, J. Jensen, V. Pierce, C. Lucchinetti, V. A. Folcik, S. Qin, J. Rottman, F. Sellebjerg, R. M. Strieter, J. L. Frederiksen, R. M. Ransohoff. 1999. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. Invest. 103:807.[Medline]
  48. Balashov, K. E., J. B. Rottman, H. L. Weiner, W. W. Hancock. 1999. CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1{alpha} and IP-10 are expressed in demyelinating brain lesions. Proc. Natl. Acad. Sci. USA 96:6873.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
A. Meiser, A. Mueller, E. L. Wise, E. M. McDonagh, S. J. Petit, N. Saran, P. C. Clark, T. J. Williams, and J. E. Pease
The Chemokine Receptor CXCR3 Is Degraded following Internalization and Is Replenished at the Cell Surface by De Novo Synthesis of Receptor
J. Immunol., May 15, 2008; 180(10): 6713 - 6724.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
K. B. Walsh, L. L. Lanier, and T. E. Lane
NKG2D Receptor Signaling Enhances Cytolytic Activity by Virus-Specific CD8+ T Cells: Evidence for a Protective Role in Virus-Induced Encephalitis
J. Virol., March 15, 2008; 82(6): 3031 - 3044.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Thapa, R. S. Welner, R. Pelayo, and D. J. J. Carr
CXCL9 and CXCL10 Expression Are Critical for Control of Genital Herpes Simplex Virus Type 2 Infection through Mobilization of HSV-Specific CTL and NK Cells to the Nervous System
J. Immunol., January 15, 2008; 180(2): 1098 - 1106.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. B. Walsh, R. A. Edwards, K. M. Romero, M. V. Kotlajich, S. A. Stohlman, and T. E. Lane
Expression of CXC Chemokine Ligand 10 from the Mouse Hepatitis Virus Genome Results in Protection from Viral-Induced Neurological and Liver Disease
J. Immunol., July 15, 2007; 179(2): 1155 - 1165.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
K. L. Hokeness, E. S. Deweerd, M. W. Munks, C. A. Lewis, R. P. Gladue, and T. P. Salazar-Mather
CXCR3-Dependent Recruitment of Antigen-Specific T Lymphocytes to the Liver during Murine Cytomegalovirus Infection
J. Virol., February 1, 2007; 81(3): 1241 - 1250.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. N. Stiles, J. L. Hardison, C. S. Schaumburg, L. M. Whitman, and T. E. Lane
T Cell Antiviral Effector Function Is Not Dependent on CXCL10 Following Murine Coronavirus Infection
J. Immunol., December 15, 2006; 177(12): 8372 - 8380.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J.-P. Chen, H.-L. Lu, S.-L. Lai, G. S. Campanella, J.-M. Sung, M.-Y. Lu, B. A. Wu-Hsieh, Y.-L. Lin, T. E. Lane, A. D. Luster, et al.
Dengue Virus Induces Expression of CXC Chemokine Ligand 10/IFN-{gamma}-Inducible Protein 10, Which Competitively Inhibits Viral Binding to Cell Surface Heparan Sulfate.
J. Immunol., September 1, 2006; 177(5): 3185 - 3192.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
R. A. Colvin, G. S. V. Campanella, L. A. Manice, and A. D. Luster
CXCR3 Requires Tyrosine Sulfation for Ligand Binding and a Second Extracellular Loop Arginine Residue for Ligand-Induced Chemotaxis
Mol. Cell. Biol., August 1, 2006; 26(15): 5838 - 5849.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
Y. Kawauchi, K. Suzuki, S. Watanabe, S. Yamagiwa, H. Yoneyama, G. D. Han, S. S. Palaniyandi, P. T. Veeraveedu, K. Watanabe, H. Kawachi, et al.
Role of IP-10/CXCL10 in the progression of pancreatitis-like injury in mice after murine retroviral infection.
Am J Physiol Gastrointest Liver Physiol, August 1, 2006; 291(2): G345 - G354.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M.-F. Hsieh, S.-L. Lai, J.-P. Chen, J.-M. Sung, Y.-L. Lin, B. A. Wu-Hsieh, C. Gerard, A. Luster, and F. Liao
Both CXCR3 and CXCL10/IFN-Inducible Protein 10 Are Required for Resistance to Primary Infection by Dengue Virus
J. Immunol., August 1, 2006; 177(3): 1855 - 1863.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Nishimura, J. E. Dusak, J. Eguchi, X. Zhu, A. Gambotto, W. J. Storkus, and H. Okada
Adoptive Transfer of Type 1 CTL Mediates Effective Anti-Central Nervous System Tumor Response: Critical Roles of IFN-Inducible Protein-10.
Cancer Res., April 15, 2006; 66(8): 4478 - 4487.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. E. Christensen, C. de Lemos, T. Moos, J. P. Christensen, and A. R. Thomsen
CXCL10 Is the Key Ligand for CXCR3 on CD8+ Effector T Cells Involved in Immune Surveillance of the Lymphocytic Choriomeningitis Virus-Infected Central Nervous System
J. Immunol., April 1, 2006; 176(7): 4235 - 4243.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. M. Gonzalez, C. C. Bergmann, C. Ramakrishna, D. R. Hinton, R. Atkinson, J. Hoskin, W. B. Macklin, and S. A. Stohlman
Inhibition of Interferon-{gamma} Signaling in Oligodendroglia Delays Coronavirus Clearance without Altering Demyelination
Am. J. Pathol., March 1, 2006; 168(3): 796 - 804.
[Abstract] [Full Text] [PDF]

Home page
 Microbiol. Mol. Biol. Rev.Home page
S. R. Weiss and S. Navas-Martin
Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome Coronavirus
Microbiol. Mol. Biol. Rev., December 1, 2005; 69(4): 635 - 664.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Kouroumalis, R. J. Nibbs, H. Aptel, K. L. Wright, G. Kolios, and S. G. Ward
The Chemokines CXCL9, CXCL10, and CXCL11 Differentially Stimulate G{alpha}i-Independent Signaling and Actin Responses in Human Intestinal Myofibroblasts
J. Immunol., October 15, 2005; 175(8): 5403 - 5411.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. Fonseca-Aten, C. M. Salvatore, A. Mejias, A. M. Rios, S. Chavez-Bueno, K. Katz, A. M. Gomez, G. H. McCracken Jr, and R. D. Hardy
Evaluation of LBM415 (NVP PDF-713), a Novel Peptide Deformylase Inhibitor, for Treatment of Experimental Mycoplasma pneumoniae Pneumonia
Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4128 - 4136.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Rhode, M. E. Pauza, A. M. Barral, E. Rodrigo, M. B. A. Oldstone, M. G. von Herrath, and U. Christen
Islet-Specific Expression of CXCL10 Causes Spontaneous Islet Infiltration and Accelerates Diabetes Development
J. Immunol., September 15, 2005; 175(6): 3516 - 3524.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
R. S. Klein, E. Lin, B. Zhang, A. D. Luster, J. Tollett, M. A. Samuel, M. Engle, and M. S. Diamond
Neuronal CXCL10 Directs CD8+ T-Cell Recruitment and Control of West Nile Virus Encephalitis
J. Virol., September 1, 2005; 79(17): 11457 - 11466.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
B. J. Lee, F. Giannoni, A. Lyon, S. Yada, B. Lu, C. Gerard, and S. R. Sarawar
Role of CXCR3 in the Immune Response to Murine Gammaherpesvirus 68
J. Virol., July 15, 2005; 79(14): 9351 - 9355.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
T. S. Kim and S. Perlman
Viral Expression of CCL2 Is Sufficient To Induce Demyelination in RAG1-/- Mice Infected with a Neurotropic Coronavirus
J. Virol., June 1, 2005; 79(11): 7113 - 7120.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
D. R. Ure, T. E. Lane, M. T. Liu, and M. Rodriguez
Neutralization of chemokines RANTES and MIG increases virus antigen expression and spinal cord pathology during Theiler's virus infection
Int. Immunol., May 1, 2005; 17(5): 569 - 579.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
A. M. Chen, N. Khanna, S. A. Stohlman, and C. C. Bergmann
Virus-Specific and Bystander CD8 T Cells Recruited during Virus-Induced Encephalomyelitis
J. Virol., April 15, 2005; 79(8): 4700 - 4708.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
Y. Jiang, J. Xu, C. Zhou, Z. Wu, S. Zhong, J. Liu, W. Luo, T. Chen, Q. Qin, and P. Deng
Characterization of Cytokine/Chemokine Profiles of Severe Acute Respiratory Syndrome
Am. J. Respir. Crit. Care Med., April 15, 2005; 171(8): 850 - 857.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
P C Ng, C W K Lam, A M Li, C K Wong, T F Leung, F W T Cheng, K L E Hon, I H S Chan, E Wong, and T F Fok
Chemokine response in children with SARS
Arch. Dis. Child., April 1, 2005; 90(4): 422 - 423.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. Zipris, E. Lien, J. X. Xie, D. L. Greiner, J. P. Mordes, and A. A. Rossini
TLR Activation Synergizes with Kilham Rat Virus Infection to Induce Diabetes in BBDR Rats
J. Immunol., January 1, 2005; 174(1): 131 - 142.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
G. VALBUENA and D. H. WALKER
EFFECT OF BLOCKING THE CXCL9/10-CXCR3 CHEMOKINE SYSTEM IN THE OUTCOME OF ENDOTHELIAL-TARGET RICKETTSIAL INFECTIONS
Am J Trop Med Hyg, October 1, 2004; 71(4): 393 - 399.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. C. Deng, X. Zeng, M. Newstead, T. A. Moore, W. C. Tsai, V. J. Thannickal, and T. J. Standiford
STAT4 Is a Critical Mediator of Early Innate Immune Responses against Pulmonary Klebsiella Infection
J. Immunol., September 15, 2004; 173(6): 4075 - 4083.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
J. E. Christensen, A. Nansen, T. Moos, B. Lu, C. Gerard, J. P. Christensen, and A. R. Thomsen
Efficient T-Cell Surveillance of the CNS Requires Expression of the CXC Chemokine Receptor 3
J. Neurosci., May 19, 2004; 24(20): 4849 - 4858.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
W. G. Glass, M. J. Hickey, J. L. Hardison, M. T. Liu, J. E. Manning, and T. E. Lane
Antibody Targeting of the CC Chemokine Ligand 5 Results in Diminished Leukocyte Infiltration into the Central Nervous System and Reduced Neurologic Disease in a Viral Model of Multiple Sclerosis
J. Immunol., April 1, 2004; 172(7): 4018 - 4025.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
I. Tsunoda, T. E Lane, J. Blackett, and